ARKG is trading at $49.16, up 3.20%, as President Donald Trump’s nomination of Heidi Overton to lead the FDA raises expectations for a more treatment- and innovation-oriented regulatory approach.
- Her vaccine and drug-approval positions introduce policy uncertainty; ARKG is outperforming the broader market’s modest gains on August 21, 2026.
- A broader risk-on backdrop, Treasury-buyback optimism, and easing liquidity concerns are supporting growth-oriented biotechnology exposures; no major U.S. economic release is scheduled.